Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug

Anesthesia and Analgesia

Volumn 86, Issue 1, 1998, Pages 111-116

  Gillin, Scott ^a   Sorkin, Linda S ^a,b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; IMMUNOMODULATING AGENT; SERINE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ESCAPE BEHAVIOR; HYPERTENSION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RAT; STARTLE REFLEX; WITHDRAWAL REFLEX;

ACETIC ACIDS; AMINES; ANALGESICS; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; GANGLIOSIDES; MALE; PAIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE;

EID: 0031975225     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199801000-00022     Document Type: Article

References (25)

1. Slart R, Sorkin L, Yaksh T, Yu AL. An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody. Pain 1997;69:119-25.
2. Handgretinger R, Baader P, Dopfer RA, et al. Phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a. Cancer Immunol Immunother 1992;35:199-204.
3. Saleh M, Khazaeli M, Wheeler R, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992;52:4342-7.
4. Xiao W-H, Yu AL, Sorkin LS. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 1997;69:145-51.
5. Group UGS. Gabapentin as add-on therapy in refractory partial epilepsy: a double blind, placebo controlled, parallel-group study. Neurology 1993;43:2292-8.
6. Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995;18: 469-81.
7. Morris GL. Efficacy and tolerability of gabapentin in clinical practice. Clin Ther 1995;17:891-900.
8. Mellick GA, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage 1995;10: 265-6.
9. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996;12:56-8.
10. Xiao W-H, Bennett GJ. Gabapentin has an anti-nociceptive effect mediated via a spinal site of action in a rat model of painful peripheral neuropathy. Analgesia 1997;2:267-73.
11. Hwang JH, Yaksh TL. The effect of intrathecal gabapentin on tactile-evoked allodynia in a surgically-induced neuropathic pain model in the rat. Reg Anesth 1997;22:249-56.
12. Hunter JC, Goas KR, Hedley LR, et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997;324:153-60.
13. Singh L, Field MJ, Ferris P, et al. The anti-epileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology 1996;127:1-9.
14. Stanfa LC, Singh L, Williams RG, Dickenson AH. Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Neuroreport 1997;8:587-90.
15. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976;17:1031-6.
16. Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53: 55-63.
17. Dixon W. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980;20:441-62.
18. Welty DF, Schielke GP, Vartanian MG, Taylor CP. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res 1993;16:175-81.
19. Pardridge WM, Choi TB. Neutral amino acid transport at the human blood brain barrier. Fed Proceed 1986;45:2073-8.
20. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-81.
21. 3H] gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993;15:303-9.
22. Löscher W, Hönack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett 1991;128:150-4.
23. Honmou O, Oyelese AA, Kocsis JD. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 1995;692:273-7.
24. Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett 1994; 169:181-4.
25. Gee NS, Brown JP, Dissanayake VUK, et al. The novel anticonvulsant drug gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-76.